title: BRAF and NRAS mutations in melanoma and melanocytic nevi.
abstract: In this report, we investigated BRAF/NRAS mutations in samples from a case-control study of melanoma and a series of benign melanocytic nevi. We evaluated potential associations between BRAF mutations and histopathologic and pigmentary characteristics of melanoma. Mutations in BRAF and NRAS were detected by sequencing microdissected/laser-captured DNA from 18 in-situ melanomas, 64 primary melanomas, and 51 nevi. Nevi showed the highest frequency of BRAF mutations (82%). BRAF mutations were identified in 29% of invasive melanomas and in only 5.6% of in-situ melanomas. Mutations in NRAS were found in 5.2% of primary melanomas, 5.9% of nevi and no NRAS mutations were seen in in-situ melanomas. A majority of the BRAF mutations observed in primary invasive melanoma were seen in superficial spreading melanoma (15/17), and melanomas with BRAF mutations were also more likely to be found on a body site that was likely to be exposed to intermittent sun exposure compared with chronic or no sun exposure (P=0.02). Tumors with BRAF mutations were also significantly more likely to occur in association with a contiguous nevus (odds ratio 3.49, 95% confidence interval 1.06-11.46), although a contiguous nevus was not found in all melanomas with a BRAF mutation. Our data support the evidence that the mitogen-activated protein kinase pathway is upregulated in a large percentage of melanocytic lesions, but these mutations are not sufficient for malignant transformation. We suggest that BRAF mutations contribute to benign melanocytic hyperplasia, but are likely to contribute to invasive melanoma only in conjunction with other mutations.
authors.affiliation: Department of Epidemiology, University of Michigan, Ann Arbor, Michigan 48109-2200, USA.
authors.forename: Jenny N
authors.initials: JN
authors.lastname: Poynter
authors.forename: James T
authors.initials: JT
authors.lastname: Elder
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Fullen
authors.forename: Rajan P
authors.initials: RP
authors.lastname: Nair
authors.forename: Maria S
authors.initials: MS
authors.lastname: Soengas
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Johnson
authors.forename: Bruce
authors.initials: B
authors.lastname: Redman
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Thomas
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Gruber
mesh_terms: D016022:Case-Control Studies; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D011905:Genes, ras / Q000235:genetics*; D006801:Humans; D007834:Lasers; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D042282:Microdissection; D008875:Middle Aged; D009154:Mutation; D009361:Neoplasm Invasiveness / Q000473:pathology; D009508:Nevus, Pigmented / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D016133:Polymerase Chain Reaction; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D017422:Sequence Analysis, DNA; D012878:Skin Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D013472:Sunlight
chemical_list: D004273:DNA, Neoplasm; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf